These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26609538)

  • 1. Comparative Immunogenicity in Rabbits of the Polypeptides Encoded by the 5' Terminus of Hepatitis C Virus RNA.
    Sominskaya I; Jansons J; Dovbenko A; Petrakova N; Lieknina I; Mihailova M; Latyshev O; Eliseeva O; Stahovska I; Akopjana I; Petrovskis I; Isaguliants M
    J Immunol Res; 2015; 2015():762426. PubMed ID: 26609538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids.
    Geissler M; Gesien A; Tokushige K; Wands JR
    J Immunol; 1997 Feb; 158(3):1231-7. PubMed ID: 9013964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specificity of humoral and cellular immune response against recombinant particles of nucleocapsid protein of human hepatitis B virus in rabbits.
    Isaguliants MG; Kadoshnikov YP; Kalinina TI; Smirnov VD; Wahren B
    Biochemistry (Mosc); 1998 May; 63(5):551-8. PubMed ID: 9632891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High efficiency prokaryotic expression and purification of a portion of the hepatitis C core protein and analysis of the immune response to recombinant protein in BALB/c mice.
    Hitomi Y; McDonnell WM; Baker JR; Askari FK
    Viral Immunol; 1995; 8(2):109-19. PubMed ID: 8825296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus precore protein augments genetic immunizations of the truncated hepatitis C virus core in BALB/c mice.
    Liao G; Wang Y; Chang J; Bian T; Tan W; Sun M; Li W; Yang H; Chen J; Zhang X; Bi S; Omata M; Jiang S
    Hepatology; 2008 Jan; 47(1):25-34. PubMed ID: 18074356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins.
    Satoi J; Murata K; Lechmann M; Manickan E; Zhang Z; Wedemeyer H; Rehermann B; Liang TJ
    J Virol; 2001 Dec; 75(24):12121-7. PubMed ID: 11711603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.
    Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L
    Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus--positive blood donors without viremia.
    Lechmann M; Ihlenfeldt HG; Braunschweiger I; Giers G; Jung G; Matz B; Kaiser R; Sauerbruch T; Spengler U
    Hepatology; 1996 Oct; 24(4):790-5. PubMed ID: 8855177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a human epitope in hepatitis C virus (HCV) core protein using a molecularly cloned antibody repertoire from a non-symptomatic, anti-HCV-positive patient.
    Barban V; Fraysse-Corgier S; Paranhos-Baccala G; Petit M; Manin C; Berard Y; Prince AM; Mandrand B; Meulien P
    J Gen Virol; 2000 Feb; 81(Pt 2):461-9. PubMed ID: 10644845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.
    Cao J; Chen Z; Ren Y; Luo Y; Cao M; Lu W; Zhao P; Qi Z
    Vaccine; 2011 May; 29(20):3714-23. PubMed ID: 21396407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Detection of antibodies to the nucleocapsid protein of Hepatitis C virus by immunoenzyme analysis using synthetic peptides of nucleocapsid N-terminal part].
    Firsova TV; Alekseenkova TI; Shibnev VA; Froesner G; Semiletov IuA
    Vopr Virusol; 2001; 46(2):21-4. PubMed ID: 11392965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus (HCV) core protein enhances the immunogenicity of a co-delivered DNA vaccine encoding HCV structural antigens in mice.
    Alvarez-Lajonchere L; González M; Alvarez-Obregón JC; Guerra I; Viña A; Acosta-Rivero N; Musacchio A; Morales J; Dueñas-Carrera S
    Biotechnol Appl Biochem; 2006 Apr; 44(Pt 1):9-17. PubMed ID: 16367740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memory T-cell-mediated immune responses specific to an alternative core protein in hepatitis C virus infection.
    Bain C; Parroche P; Lavergne JP; Duverger B; Vieux C; Dubois V; Komurian-Pradel F; Trépo C; Gebuhrer L; Paranhos-Baccala G; Penin F; Inchauspé G
    J Virol; 2004 Oct; 78(19):10460-9. PubMed ID: 15367612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A truncated HCV core protein elicits a potent immune response with a strong participation of cellular immunity components in mice.
    Alvarez-Obregón JC; Dueñas-Carrera S; Valenzuela C; Grillo JM
    Vaccine; 2001 Jul; 19(28-29):3940-6. PubMed ID: 11427269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterisation of a panel of monoclonal antibodies raised against recombinant HCV core protein.
    Ferns RB; Tuke PW; Sweenie CH
    J Med Virol; 1996 Nov; 50(3):221-9. PubMed ID: 8923286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination.
    Vidalin O; Tanaka E; Spengler U; Trépo C; Inchauspé G
    DNA Cell Biol; 1999 Aug; 18(8):611-21. PubMed ID: 10463057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoreactivity of HCV/HBV epitopes displayed in an epitope-presenting system.
    Chen Y; Xiong X; Liu X; Li J; Wen Y; Chen Y; Dai Q; Cao Z; Yu W
    Mol Immunol; 2006 Feb; 43(5):436-42. PubMed ID: 16337486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the full-length HCV core subgenome from HCV gentoype-1a and genotype-3a and evaluation of the antigenicity of translational products.
    Ansari MA; Irshad M; Agarwal SK; Chosdol K
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):806-13. PubMed ID: 23442416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A hepatitis C virus core polypeptide expressed in chloroplasts detects anti-core antibodies in infected human sera.
    Madesis P; Osathanunkul M; Georgopoulou U; Gisby MF; Mudd EA; Nianiou I; Tsitoura P; Mavromara P; Tsaftaris A; Day A
    J Biotechnol; 2010 Feb; 145(4):377-86. PubMed ID: 19969031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial.
    Alvarez-Lajonchere L; Shoukry NH; Grá B; Amador-Cañizares Y; Helle F; Bédard N; Guerra I; Drouin C; Dubuisson J; González-Horta EE; Martínez G; Marante J; Cinza Z; Castellanos M; Dueñas-Carrera S
    J Viral Hepat; 2009 Mar; 16(3):156-67. PubMed ID: 19017255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.